Skip to main content

Table 3 Demographics of the study cohort and those with a medical or pharmacologic contraindication to mefloquine use, U.S. military personnel deployed to Afghanistan, 2007.

From: Prevalence of contraindications to mefloquine use among USA military personnel deployed to Afghanistan

   Contraindication(s) to mefloquine
  Study cohort Medical Pharmacologic Either or Both
  Number (%) Number (%) Number (%) Number (%)
Total 11725 (100) 558 (100) 837 (100) 1127 (100)
Gender     
   Male 10614 (90.5) 463 (83.0) 670 (80.0) 916 (81.3)
   Female 1111 (9.5) 95 (17.0) 167 (20.0) 211 (18.7)
Race     
   White 8552 (72.9) 428 (76.7) 626 (74.8) 846 (75.1)
   Black 1967 (16.8) 84 (15.1) 118 (14.1) 171 (15.2)
   Other 1206 (10.3) 46 (8.2) 93 (11.1) 110 (9.8)
Prior deployments     
   0 7119 (60.7) 315 (56.5) 494 (59.0) 660 (58.6)
   1 3442 (29.4) 175 (31.4) 256 (30.6) 347 (30.8)
   2+ 1164 (9.9) 68 (12.2) 87 (10.4) 120 (10.6)
Military specialty     
   Combat 2818 (24.0) 112 (20.1) 153 (18.3) 214 (19.0)
   Non-combat 8907 (76.0) 446 (79.9) 684 (81.7) 913 (81.0)
Age     
   18–19 521 (4.4) 27 (4.8) 18 (2.2) 38 (3.4)
   20–29 7701 (65.7) 356 (63.8) 508 (60.7) 702 (62.3)
   30–39 2774 (23.7) 138 (24.7) 240 (28.7) 301 (26.7)
   40–49 688 (5.9) 37 (6.6) 66 (7.9) 81 (7.2)
   50+ 41 (0.3) 0 (0.0) 5 (0.6) 5 (0.4)